Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNG | P07510 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | CHRND | Q07001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23448243 | 0.95 | CHRNA1 (0.31) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL23447893 | 0.94 | CHRNA1 (0.32) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL24839225 | 0.94 | SLC6A2 (0.33) | GPR84CYP11B1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23448207 | 0.94 | GPR84 (0.32) | GPR84SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24838890 | 0.92 | CHRNA1 (0.32) | GPR84CYP11B1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23448401 | 0.92 | GPR84 (0.32) | GPR84SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23224422 | 0.91 | CHRNA1 (0.32) | CYP11B1CHRNA1CHRNGCHRNB1CHRNB2 | |
| SCHEMBL26060379 | 0.91 | GSTP1 (0.31) | GPR84SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL24839219 | 0.90 | SLC6A2 (0.32) | GPR84CYP11B1CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23448735 | 0.90 | CHRNA1 (0.32) | CYP11B1CHRNA1CHRNGCHRNB1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002420-A1 | ORGANIC LIGHT-EMITTING ELEMENT | LG CHEM, LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| WO-2021107737-A1 | ORGANIC LIGHT-EMITTING ELEMENT | 주식회사 엘지화학 | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002420-A1 | ORGANIC LIGHT-EMITTING ELEMENT | CYBA, CRY1, CYP1A1 | GPR84 2665/4885CYP11B1 213/4885CHRNA1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.